Onconova Therapeutics (NASDAQ: ONTX) Lowered to Hold at Zacks Investment Research

Onconova Therapeutics (NASDAQ: ONTX) was downgraded by  Zacks Research  from a “get” score to a “hold” score in a research note released to investors on Thursday, reports.

According to Zacks, “Onconova Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on discovering and also developing little molecule medication candidates to deal with cancer. The Business‘s items under various phases of development consist of Rigosertib intravenous (IV), Rigosertib Oral, Rigosertib IV, ON 013105 and also Recilisib. Onconova Therapeutics, Inc. is headquartered in Newtown, Pennsylvania. “

Numerous various other equities research experts also lately commented on the company. Noble Financial reissued a “acquire” rating and provided a $11.00 rate objective on shares of Onconova Therapeutics in a report on Thursday, September 23rd. Guggenheim dropped their cost target on Onconova Therapeutics from $29.00 to $12.00 and also set a “buy” score on the stock in a research note on Tuesday, September 28th.

NASDAQ: ONTX opened at $2.25 on Thursday. Onconova Therapeutics has a twelve month low of $2.22 as well as a twelve month high of $28.95. Business has a 50 day relocating typical cost of $2.90 and a two-hundred day relocating average price of $4.16. The company has a market cap of $46.76 million, a P/E proportion of -1.82 and also a beta of 1.67.

Onconova Therapeutics (NASDAQ: ONTX) last launched its quarterly incomes results on Thursday, November 11th. The biopharmaceutical company reported ($ 0.22) earnings per share for the quarter, topping analysts’ consensus quotes of ($ 0.33) by $0.11. Onconova Therapeutics had a negative return on equity of 59.78% as well as a negative internet margin of 8,294.27%. The firm had revenue of $0.06 million during the quarter, compared to the consensus estimate of $0.06 million. Throughout the very same quarter in the previous year, the company uploaded ($ 0.45) EPS. En masse, research analysts forecast that Onconova Therapeutics will certainly upload -1.18 EPS for the present year.

A variety of hedge funds have actually just recently bought and sold shares of ONTX. GSA Resources Allies LLP purchased a brand-new placement in Onconova Therapeutics throughout the 3rd quarter worth $922,000. Hudson Bay Funding Management LP bought a brand-new position in shares of Onconova Therapeutics in the third quarter worth $635,000. Pura Vida Investments LLC purchased a new setting in shares of Onconova Therapeutics in the third quarter worth $575,000. CVI Holdings LLC purchased a new position in shares of Onconova Therapeutics in the third quarter worth $493,000. Finally, Dimensional Fund Advisors LP bought a brand-new position in shares of Onconova Therapeutics in the 2nd quarter worth $509,000. Hedge funds and other institutional investors have 13.36% of the business’s stock.

About Onconova Therapeutics

Onconova Therapeutics, Inc is a clinical-stage biopharmaceutical business, which engages in the identification and growth of oncology therapeutics. It focuses on discovering and also establishing little molecule medication candidates to deal with cancer cells. The business was founded by Ramesh Kumar and also E. Premkumar Reddy on December 22, 1998 and is headquartered in Newtown, PA

. Get a totally free copy of the Zacks research report on Onconova Therapeutics (ONTX).

For more information about research offerings from Zacks Investment Research, browse through

This immediate information alert was generated by narrative scientific research technology and also monetary data from Market in order to offer viewers with the fastest and also most precise reporting. This tale was reviewed by Market’s content group before publication. 



Prior to you think about Onconova Therapeutics, you’ll intend to hear this.

Market monitors Wall Street’s premier and also best performing research analysts and also the stocks they suggest to their customers each day. Market has identified the five stocks that cover experts are quietly whispering to their clients to buy currently prior to the more comprehensive market catches on … and Onconova Therapeutics wasn’t on the listing.

While Onconova Therapeutics presently has a “Buy” ranking among analysts, top-rated analysts think these 5 stocks are much better acquires.